ALT testing in the early stages of a patient’s disease can facilitate timely treatment as well as help monitor the development of NAFLD and the progression of the disease from simple lipidosis or steatosis to more advanced stages [9]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.